Company Overview
Tiziana Life Sciences is a dual-listed clinical stage biotechnology company focused on the discovery and development of novel molecules to treat human disease in oncology and immunology. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
Tiziana Life Sciences: Robust Pipeline with Multiple Near-Term Catalysts
Pipeline Overview & Upcoming Milestones
Foralumab
Foralumab (TZLS-401) has significant potential as the only fully human engineered anti-human CD3 antibody in clinical development with advantages of short duration of treatment regimen, reduced immunogenicity and prevention of the life-threatening cytokine release syndrome.
- Patent filed on use of Foralumab to enhance success of CAR-T therapy
- IND submission in COVID-19 - Q2 2021
- Phase 1b/2 trial with orally administered Foralumab in Crohn’s Disease patients anticipated completion – Q2 2021
- Phase 2 trial with nasally administered Foralumab in progressive multiple sclerosis (pro-MS) patients anticipated completion – Q2 2021
TZLS-501 (anti-IL6R)
TZLS-501 is a fully human anti IL-6R monoclonal antibody with a novel mechanism of action. The mAb possesses a high affinity for IL-6R and the IL-6/IL-6R complex and effectively blocks the complex even at high IL-6 circulating levels, showing superiority and overcoming the limitations of other IL-6 pathway drugs.
- Development of inhalation technology to deliver stable aerosols directly in lungs – Q2 2021
Milciclib
The Company’s lead compound, milciclib, is a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDKs) involved in cell division as well as several other protein kinases.
- Initiate Phase 2b in HCC patients with Milciclib in combination with a TKI – Q3 2021
Tiziana Life Sciences Investor Webinar – January 2021
Investment Highlights
-
Transformational platform technologies
- Proprietary oral, nasal and inhaled formulation technologies to transform immunotherapies with Monoclonal Antibodies currently administered intravenously
-
Phase 2 oral immunotherapy study for Crohn’s Disease (CD)
- Phase 2 clinical study with orally administered Foralumab, a fully human anti-CD3 mAb
- Collaboration with Parexel Biotech
-
Reported positive top-line data from COVID-19 trial in Jan. 2021
- Innovative technology enables direct delivery of anti-IL6 receptor monoclonal antibodies into the lung using a handheld inhaler or nebulizer
- Could be effective against SARS, MERS, and all variants of coronaviruses
- Planning Phase 2 study in moderate to severe COVID-19 patients
-
Strong intellectual property protections
- 174 foreign patents and 19 U.S. patents issued
-
Proven leadership team with ‘bench to market’ experience
- Entrepreneurial success in biotech deals; CEO is co-founder, Synergy Pharma; Executive Chairman founded and chaired two biotechs with $2B+ market caps. Exemplary scientific advisory board with world renowned key opinion leaders
- FDA approved expanded access use for Foralumab treating a Secondary Progressive Multiple Sclerosis patient
- Successfully spun off StemPrintER business in Q4 2020
Value Proposition
Tiziana has developed proprietary oral, nasal, and inhaled formulation technologies that could transform immunotherapies with Monoclonal Antibodies currently administered intravenously for multiple indications. Through multiple Phase 2 trials underway and/or planned, the Company is positioned for a steady stream of milestone achievements over the next several quarters, including launch of a Phase 2 COVID-19 trial. Led by a world-class leadership team and scientific advisory board with a collective 76 years of experience in medical technology and more than 100 medical product launches, Tiziana is ideally positioned to execute on its robust corporate strategy.
Contact Information:
RedChip.com | 1-800-REDCHIP (733-2447)
Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
Tiziana Life Sciences (TLSA) is a client of RedChip Companies, Inc. TLSA agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2020, increasing to $15,000 monthly in August 2020, and $20,000 monthly in October 2020, for RedChip investor awareness services.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.
Privacy Policy
Website Powered By
© 2021 Redchip Companies, Inc.